Cyclacel Pharmaceuticals (CYCC) Expected to Announce Earnings on Wednesday

by · The Cerbat Gem

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $0.03 million for the quarter.

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last issued its earnings results on Wednesday, April 2nd. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million.

Cyclacel Pharmaceuticals Stock Performance

Cyclacel Pharmaceuticals stock opened at $0.25 on Monday. Cyclacel Pharmaceuticals has a fifty-two week low of $0.17 and a fifty-two week high of $3.08. The company has a market capitalization of $52.08 million, a PE ratio of -0.03 and a beta of 0.15. The company has a 50 day moving average price of $0.27 and a 200-day moving average price of $0.38.

Cyclacel Pharmaceuticals Announces Dividend

The company also recently announced a dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 29th were given a dividend of $0.15 per share. The ex-dividend date was Tuesday, April 29th. Cyclacel Pharmaceuticals’s dividend payout ratio (DPR) is presently -4.29%.

Insider Buying and Selling at Cyclacel Pharmaceuticals

In related news, CEO David E. Lazar sold 194,628,820 shares of Cyclacel Pharmaceuticals stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total transaction of $5,838,864.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 68.00% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Cyclacel Pharmaceuticals in a research report on Friday. They set a “sell” rating on the stock.

Get Our Latest Stock Report on Cyclacel Pharmaceuticals

About Cyclacel Pharmaceuticals

(Get Free Report)

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.

See Also